Septic Shock- Pipeline Insight, 2025

This “Septic Shock- Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Septic Shock pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Septic Shock: Understanding

Septic Shock: Overview

Septic Shock, is defined as sepsis associated with hypotension and perfusion abnormalities despite the provision of adequate fluid (volume) resuscitation. It is a complication of sepsis that leads to severe sepsis and septic shock. Sepsis develops due to infections such as bacterial, fungal, and viral. According to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), septic shock is defined by persisting hypotension that requires vasopressors to maintain a mean arterial pressure of 65 mmHg or higher and a serum lactate level greater than 2 mmol/L (18 mg/dL) despite adequate volume resuscitation.

The symptoms of septic shock include hypotension, confusion or disorientation, diarrhea, nausea and vomiting, and cold, clammy and pale skin.

The risk of septic shock is higher in newborns and infants, elderly people, pregnant women, and individuals with chronic diseases. The chronic diseases that increase the risk of septic shock include diabetes, cirrhosis, cancer, AIDS/HIV, kidney and heart disease. Infections that commonly lead to septic shock include urinary tract infections (UTI), pneumonia, stomach infections, and skin infections. The pathogenesis involves a complex response of cellular activation that triggers the release of a multitude of proinflammatory mediators. This inflammatory response causes activation of leukocytes and endothelial cells, as well as activation of the coagulation system. Cytokines tumor necrosis factor alpha (TNF-α) and interleukin-1 (IL-1) are central to the pathophysiology of septic shock and act synergistically to induce hypotension in experimental models, a number of other vital mediators are also known to play a major role including high-mobility group box 1 (HMGB1) protein.

The diagnosis of Septic Shock is confirmed when patients meet the criteria for sepsis and also requires vasopressors in addition to fluids to maintain adequate blood flow. The hallmarks of sepsis and septic shock are changes that occur at the microvascular and cellular level and may not be clearly manifested in the vital signs or clinical examination.The treatment may include intravenous antibiotics, vasopressors, insulin, and corticosteroids. Large amounts of intravenous fluids will be administered to treat dehydration and help increase blood pressure and blood flow to the organs. Surgery may be performed to remove a source of infection, such as draining a pus-filled abscess or removing infected tissue. Prevention of sepsis and septic shock is based on good clinical practices to reduce the incidence of infections, particularly in high-risk populations.

'Septic Shock- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Septic Shock pipeline landscape is provided which includes the disease overview and Septic Shock treatment guidelines. The assessment part of the report embraces, in depth Septic Shock commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Septic Shock collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Septic Shock R&D. The therapies under development are focused on novel approaches to treat/improve Septic Shock.

Septic Shock Emerging Drugs Chapters

This segment of the Septic Shock report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Septic Shock Emerging Drugs

VBI-S: Vivacelle Bio

VBI-S is the first product in a clinical trial treating an aspect of septic shock to have 100% efficacy in phase IIA results and achieve all of its endpoints in the past 20 years. The Phase III VBI-S trial is also fully funded. VBI-1 utilizes the same platform technology to treat hemorrhagic shock. VBI-1 cleared to start phase II. VBI-S, which is administered intravenously, reversibly absorbs NO, reducing the bioavailability of NO. This first of its kind approach reduces the bioavailability of NO without interfering with its production or essential cellular interactions. The drug is currently being investigated in the Phase III stage of development for the treatment of Septic Shock.

Adrecizumab: Adrenomed

Adrecizumab is a proprietary humanized monoclonal adrenomedulli-specific antibody. This targeted therapy inhibits excessive circulating sepsis-induced ADM and stimulates protective effects on the endothelial barrier, and decreases interstitial vasodilatory effects. Binding of the monoclonal antibody Adrecizumab to bioactive adrenomedullin (bio-ADM) in the blood traps and stabilizes the peptide-hormone, resulting in increased ADM concentrations within the blood vessels. Adrecizumab is currently in Phase II clinical developmental stage for the treatment of septic shock and acute heart failure. Adrecizumab treatment significantly improved all clinically relevant endpoints such as reduction of vascular leakage and vasopressor demand, stabilization of the circulation, normalization of fluid balance and kidney function. In preclinical septic shock models, Adrecizumab reduced the mortality by 50%. The drug is currently being investigated in the Phase II stage of development for the treatment of Septic Shock.

Septic Shock: Therapeutic Assessment

This segment of the report provides insights about the different Septic Shock drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Septic Shock

There are approx. 10+ key companies which are developing the therapies for Septic Shock. The companies which have their Septic Shock drug candidates in the most advanced stage, i.e. Phase III include, Vivacelle Bio.

Phases

The report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Septic Shock pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Septic Shock: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Septic Shock therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Septic Shock drugs.

Septic Shock Report Insights

• Septic Shock Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Septic Shock Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Septic Shock drugs?
• How many Septic Shock drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Septic Shock?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Septic Shock therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Septic Shock and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vivacelle Bio
• Adrenomed
• Inotrem
• Northern Therapeutics
• MYND Life Sciences

Key Products

• VBI-S
• Adrecizumab
• Nangibotide
• GEM00220
• ABCF1 modulators

This product will be delivered within 2 business days.